Johnson & Johnson raised full-year forecasts after reporting blowout earnings, attracting investors amid market volatility and geopolitical risks.
Johnson & Johnson (NYSE: JNJ) shares climbed 22% in the first half of 2024, driven by robust earnings and a raised full-year outlook. The healthcare giant benefited from investor rotation into stable, high-growth assets amid geopolitical uncertainties and AI market risks.
The company’s pharmaceutical and medtech divisions, bolstered by in-house research and acquisitions, have sustained earnings growth. J&J recently spun off its consumer health unit, Kenvue, to focus on higher-margin segments. The move preceded the loss of exclusivity for its blockbuster immunology drug Stelara.
Investors flocked to J&J’s defensive profile, as demand for medical products remains resilient regardless of market conditions. The latest earnings beat reinforced confidence in its long-term growth strategy.